Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 StudyThomas E. Witzig, Antonio Gualberto, Dolores Caballero et al.|Blood|2019Cited by 10
P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDYWon-Seog Kim, Steven M. Horwitz, Jake Shortt et al.|HemaSphere|2023Cited by 4
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 StudyThomas E. Witzig, Antonio Gualberto, Lubomir Sokol et al.|Blood|2018Cited by 2